Ipsos’ Global Core Vaccines Monitor uncovers evolving attitudes and perceptions around vaccines, with a focus on COVID-19, from the perspectives of HCPs, pharmacists and consumers. This intuitive Tableau interface gives you instant access to all metrics collated in the Monitor, allowing you to identify and track strategic enhancements needed in this ever-changing landscape.
Ipsos’ Global RSV Monitor uncovers evolving attitudes and perceptions around RSV vaccination/immunisation, from the perspectives of HCPs, pharmacists and consumers. This intuitive Tableau interface gives you instant access to all metrics collated in the Monitor, allowing you to identify and track strategic enhancements needed in this ever-changing landscape.
Navigating the evolving landscape of HIV treatment requires a deep understanding of treatment advances in recent years – notably, the approval of Biktarvy and Dovato. By applying decision tree and correlation analysis to over 20,000 real-world patient records, we uncover the critical factors driving prescription decisions and shaping the future of HIV care in Europe.
The FDA approval of Capvaxive in 2024 brings renewed competitive edge to the pneumococcal vaccines market, offering a shot that protects against eight new types of bacterial strains not found in other vaccines. Navigating this shifting landscape requires an understanding of both HCP and consumer attitudes towards such vaccines and future anticipated uptake. Using insights from the Ipsos Core Vaccines Monitor, this report facilitates optimised vaccine market strategies and identifies new opportunities for brand success.
Unlike other common respiratory tract infections, there are currently no available vaccines to protect against hMPV; however, multiple developmental candidates are being explored. Using insights from the Ipsos RSV Monitor, this report enables an understanding of HCP and consumer attitudes towards this respiratory virus and potential vaccines. A go-to landscaping exercise for those with or assessing assets in this field.
Additional pertinence has been given to combination vaccines since COVID; current developmental assets include shots that combine COVID-19 + influenza, and COVID-19 + influenza + RSV. Using insights from the Ipsos Core Vaccines Monitor, this report presents both HCP and consumer attitudes towards the combination vaccines in development and how to respond to them for optimised market strategies.
Understanding the motivations behind vaccine hesitancy and the factors contributing to vaccine fatigue are imperative to achieving and maintaining market stature. In this report, insights from the Ipsos Core Vaccines Monitor illuminate both HCP and consumer perceptions of vaccine hesitancy, reasons for hesitancy, vaccine fatigue and drivers and barriers to getting vaccinated - a key grounding on which to build appropriate messaging and support strategies.